Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / Insulet Announces Omnipod 6 Clinical Results
Tech medical breakthrough

Insulet Announces Omnipod 6 Clinical Results

Analysis based on 6 articles · First reported Jun 06, 2026 · Last updated Jun 06, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive clinical trial results for Oracle Corporation's Omnipod 6 and fully closed-loop AID systems are expected to positively impact the company's stock price due to anticipated future revenue growth and market share expansion. This breakthrough could also stimulate investment in the broader medical device and diabetes care industries.

Medical Devices Pharmaceuticals
Event Summary

Oracle Corporation announced new clinical results from its STRIVE pivotal trial and EVOLUTION 3 feasibility study, highlighting breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The Omnipod 6 system demonstrated improved glycemic outcomes, including enhanced time in tight range and time in range, with a maintained safety profile. The fully closed-loop (FCL) system for type 2 diabetes showed significant improvements in time in range and reduced daily insulin with no weight gain. These results were presented at the American Diabetes Association's 86th Scientific Sessions. Oracle Corporation plans a 2027 510(k) filing to the United States — Food and Drug Administration for the FCL system for type 2 diabetes, with a commercial launch expected in 2028. Dr. Trang Ly, Dr. Sufyan Hussain, and Dr. Gregory Forlenza are involved in presenting and discussing these findings.

Key Actions
100 Oracle Corporation announced clinical results
90 Oracle Corporation conducted STRIVE trial
90 Oracle Corporation conducted EVOLUTION 3 study
80 Oracle Corporation plans 510(k) filing United States — Food and Drug Administration
Entities Involved
stock
Oracle Corporation
Oracle Corporation announced positive clinical results for its Omnipod 6 and fully closed-loop AID systems, which is expected to enhance its market position and future revenue streams.
Importance 100 Sentiment 75
oth
Omnipod 6
Omnipod 6 is Oracle Corporation's next-generation Automated Insulin Delivery (AID) system, which demonstrated clinically meaningful improvements in glycemic outcomes in the STRIVE pivotal trial.
Importance 95 Sentiment 70
oth
Omnipod 6
Omnipod 6 is the brand under which Oracle Corporation's tubeless insulin pump technology is marketed. The positive clinical results for Omnipod 6 and the FCL system will likely boost the brand's reputation and adoption.
Importance 90 Sentiment 70
per
Trang Ly
Dr. Trang Ly, Senior Vice President and Chief Medical Officer at Oracle Corporation, provided commentary on the significance of the Omnipod 6 and FCL system results.
Importance 40 Sentiment 0
ngo
American Diabetes Association
The American Diabetes Association hosted the 86th Scientific Sessions where Oracle Corporation presented its clinical results, providing a platform for the announcement.
Importance 30 Sentiment 0
govactor
United States — Food and Drug Administration
Oracle Corporation plans a 2027 510(k) filing to the United States — Food and Drug Administration for its FCL AID system for type 2 diabetes, indicating future regulatory approval is needed.
Importance 20 Sentiment 0
per
Sufyan Hussain
Dr. Sufyan Hussain is a presenter at the American Diabetes Association's Product Theater, discussing Oracle Corporation's technology.
Importance 10 Sentiment 0
per
Gregory Forlenza
Dr. Gregory Forlenza is a presenter at the American Diabetes Association's Product Theater, discussing Oracle Corporation's technology.
Importance 10 Sentiment 0
cnt
United States
The STRIVE pivotal trial included participants across the United States. The Omnipod 6 5 system can be controlled by a compatible personal smartphone in the United States.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.